Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Researchers reveal how an ingredient in traditional Chinese medicine may hold the secret to creating a new treatment for ...

The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...

A new research paper titled "Initiation of tumor dormancy by the lymphovascular embolus" has been published in Oncotarget ...

which has a PI3K/mTOR drug in development for lung and prostate cancer. SignalRX Therapeutics is also reading a PI3K pan inhibitor for phase 2 development after testing it in a range of solid ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 ...

The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently ...

【导读】乳腺癌（BC）是一种全球范围内影响女性的常见恶性肿瘤。尽管TBL2已被证实参与多种细胞内信号通路，但其在乳腺癌中的确切功能尚不明确。11月5日，中山大学/南华大学研究团队共同在期刊《Advanced Science》上发表了题为“TBL2 ...

The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma.

▎药明康德内容团队编辑罗氏（Roche）公司日前宣布其口服小分子疗法Itovebi（inavolisib）在临床3期试验INAVO120的积极结果发布于《新英格兰医学杂志》（NEJM）。该试验结果支持Itovebi在本月获美国FDA批准，与CDK4/ ...